Oral Cavity Carcinoma
14
4
8
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
14.3%
2 terminated out of 14 trials
66.7%
-19.8% vs benchmark
7%
1 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (14)
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls
Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia
Role of Acetaldehyde in the Development of Oral Cancer
Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment
Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
Behavior Changing Intervention for Smokeless Tobacco and Betel Quid Use in Adolescents
Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer